Cited by 527Genetics and Neurodevelopmental DisordersNeuroscience and Neuropharmacology ResearchEpilepsy research and treatment

The DOI matches its Crossref record; 57 of the 60 references it cites were found in a registry or an index.

Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP

Yan, Q.J., Rammal, M., Tranfaglia, M., Bauchwitz, R.P.·2005·Neuropharmacology

DOI 10.1016/j.neuropharm.2005.06.004

Open this paper in CoChat — free account

Abstract

Fragile X Syndrome is the most common form of inherited mental retardation worldwide. A Fragile X mouse model, fmr1(tm1Cgr), with a disruption in the X-linked Fmr1 gene, has three substantial deficits observed in several strains: (1) sensitivity to audiogenic seizures (AGS), (2) tendency to spend significantly more time in the center of an open field, and (3) enlarged testes. Alterations in metabotropic glutamate receptor group I signaling were previously identified in the fmr1(tm1Cgr) mouse. In this study, we examined the effect of MPEP, an antagonist of the group I metabotropic glutamate receptor mGluR5, on audiogenic seizures and open field activity of fmr1(tm1Cgr) mice. Genetic analysis revealed synergistic reactions between fmr1(tm1Cgr) and inbred AGS alleles. In addition, AGS sensitivity due to the fmr1(tm1Cgr) allele was restricted during development. Examination of phenotypes combining mGluR5 inhibition and Fmr1 mutation indicated that absence of FMRP may affect mGluR5 signaling through indirect as well as direct pathways. All strains of fmr1(tm1Cgr) mice tested (FVB/NJ, C57BL/6J, and an F1 hybrid of the two) had a more excitable AGS pathway than wild-type, and consequently required more MPEP to achieve seizure suppression. At high doses of mGluR5 antagonists, a Fragile X specific tolerance (loss of drug activity) was observed. The tolerance effect could be overcome by a further increase in drug dose. In open field tests, MPEP reduced fmr1(tm1Cgr) center field behavio…

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.neuropharm.2005.06.004

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review.
Prut, L., & Belzung, C. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01272-x · Cited by 3,190
The open-field test: A critical review.
WALSH, R. N., & Cummins, R. A. (1976) · Psychological Bulletin · doi:10.1037/0033-2909.83.3.482 · Cited by 2,389
The mGluR theory of fragile X mental retardation
Bear, M. F., Huber, K. M., & Warren, S. T. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.04.009 · Cited by 1,580
Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: A novel test of anxiety in the rat
Pellow, S., & File, S. E. (1986) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(86)90552-6 · Cited by 1,534
Altered synaptic plasticity in a mouse model of fragile X mental retardation
Huber, K. M., Gallagher, S. M., Warren, S. T., & Bear, M. F. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122205699 · Cited by 1,349
Fmr1 knockout mice: A model to study fragile X mental retardation
THEDUTCHBELGIANFRAGILEXCONSOR (1994) · Cell · doi:10.1016/0092-8674(94)90569-x · Cited by 1,108
Abnormal dendritic spines in fragile X knockout mice: Maturation and pruning deficits
Comery, T. A., Harris, J. B., Willems, P. J., Oostra, B. A., Irwin, S. A., Weiler, I. J., & Greenough, W. T. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.10.5401 · Cited by 1,046
Deficient cerebellar long-term depression and impaired motor learning in mGluR1 mutant mice
Aiba, A., Kano, M., Chen, C., Stanton, M. E., Fox, G. D., Herrup, K., Zwingman, T. A., & Tonegawa, S. (1994) · Cell · doi:10.1016/0092-8674(94)90205-4 · Cited by 930
Metabotropic glutamate receptors: electrophysiological properties and role in plasticity
Anwyl, R. (1999) · Brain Research Reviews · doi:10.1016/s0165-0173(98)00050-2 · Cited by 799
Induction of LTP in the hippocampus needs synaptic activation of glutamate metabotropic receptors
Bashir, Z. I., Bortolotto, Z. A., Davies, C. H., Berretta, N., Irving, A. J., Seal, A., Henley, J. M., Jane, D. E., Watkins, J. C., & Collingridge, G. L. (1993) · Nature · doi:10.1038/363347a0 · Cited by 733

Show all 60 references

Sorted by citations

Items 301–400 of 527

MPEP reduces seizure severity in Fmr-1 KO mice over expressing human Abeta.
Westmark, C. J., Westmark, P. R., & Malter, J. S. (2009) · PubMed Central · Cited by 29
Dual Regulation of Fragile X Mental Retardation Protein by Group I Metabotropic Glutamate Receptors Controls Translation-Dependent Epileptogenesis in the Hippocampus
Zhao, W., Chuang, S.-C., Bianchi, R., & Wong, R. K. S. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.2915-10.2011 · Cited by 29
Flies as the ointment: Drosophila modeling to enhance drug discovery
Bell, A. J., McBride, S. M. J., & Dockendorff, T. C. (2009) · Fly · doi:10.4161/fly.3.1.7774 · Cited by 30
Efficacy switching SAR of mGluR5 allosteric modulators: Highly potent positive and negative modulators from one chemotype
Sams, A. G., Mikkelsen, G. K., Brodbeck, R. M., Pu, X., & Ritzén, A. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.03.103 · Cited by 28
Development of mavoglurant and its potential for the treatment of fragile X syndrome
Gomez‐Mancilla, B., Berry‐Kravis, E., Hagerman, R. J., von Raison, F., Apostol, G., Ufer, M., Gasparini, F., & Jacquemont, S. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.857400 · Cited by 30
Adenosine A2A receptor inhibition reduces synaptic and cognitive hippocampal alterations in Fmr1 KO mice
Ferrante, A., Boussadia, Z., Borreca, A., Mallozzi, C., Pedini, G., Pacini, L., Pèzzola, A., Armida, M., Vincenzi, F., Varani, K., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01238-5 · Cited by 26
Mouse models of fragile X-related disorders
Willemsen, R., & Kooy, R. F. (2023) · Disease Models & Mechanisms · doi:10.1242/dmm.049485 · Cited by 30
Modeling Social Communication Deficits in Mouse Models of Autism
Michetti, C. (2012) · Autism - Open Access · doi:10.4172/2165-7890.s1-007 · Cited by 30
A TrkB agonist and ampakine rescue synaptic plasticity and multiple forms of memory in a mouse model of intellectual disability
Seese, R. R., Le, A. A., Wang, K., Cox, C. D., LYNCH, G. S., & Gall, C. M. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104604 · Cited by 29
Differential effects of protein phosphatases in the recycling of metabotropic glutamate receptor 5
Mahato, P. K., Pandey, S., & Bhattacharyya, S. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.08.031 · Cited by 27
(3-Cyano-5-fluorophenyl)biaryl Negative Allosteric Modulators of mGlu5: Discovery of a New Tool Compound with Activity in the OSS Mouse Model of Addiction
Lindsley, C. W., Bates, B. S., Menon, U. N., Jadhav, S. B., Kane, A. S., Jones, C. K., Rodriguez, A. L., Conn, P. J., Olsen, C. M., Winder, D. G., et al. (2011) · ACS Chemical Neuroscience · doi:10.1021/cn100099n · Cited by 26
Inhibition of GluN2A NMDA receptors ameliorates synaptic plasticity deficits in the Fmr1−/y mouse model
Lundbye, C. J., Toft, A. K. H., & Banke, T. G. (2018) · The Journal of Physiology · doi:10.1113/jp276304 · Cited by 26
(S)-5-(2′-Fluorophenyl)-N,N-dimethyl-1,2,3,4-tetrahydronaphthalen-2-amine, a Serotonin Receptor Modulator, Possesses Anticonvulsant, Prosocial, and Anxiolytic-like Properties in an Fmr1 Knockout Mouse Model of Fragile X Syndrome and Autism Spectrum Disorder
Armstrong, J. L., Casey, A. B., Saraf, T. S., Mukherjee, M., Booth, R. G., & Canal, C. E. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00101 · Cited by 26
Epilepsy Characteristics in Neurodevelopmental Disorders: Research from Patient Cohorts and Animal Models Focusing on Autism Spectrum Disorder
Chakraborty, S., Parayil, R., Mishra, S., Nongthomba, U., & Clement, J. P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810807 · Cited by 29
Design and synthesis of novel heterobiaryl amides as metabotropic glutamate receptor subtype 5 antagonists
Kulkarni, S. S., & Newman, A. H. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.12.083 · Cited by 26
Rethinking metabotropic glutamate receptor 5 pathological findings in psychiatric disorders: implications for the future of novel therapeutics
Newell, K. A., & Matosin, N. (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-23 · Cited by 26
Fragile X syndrome: mechanistic insights and therapeutic avenues regarding the role of potassium channels
Lee, H. Y., & Jan, L. Y. (2012) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2012.03.010 · Cited by 25
Targeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromes
Wang, H., Pati, S. B. B., Pozzo‐Miller, L. D., & Doering, L. C. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00055 · Cited by 28
SIPA1L1/SPAR1 Interacts with the Neurabin Family of Proteins and is Involved in GPCR Signaling
Matsuura, K., Kobayashi, S., Konno, K., Yamasaki, M., Horiuchi, T., Senda, T., Hayashi, T., Satoh, K., Arima-Yoshida, F., Iwasaki, K., et al. (2022) · Journal of Neuroscience · doi:10.1523/jneurosci.0569-21.2022 · Cited by 25
Amygdala Regulation of Fear and Emotionality in Fragile X Syndrome
Olmos-Serrano, J. L., & Corbin, J. G. (2011) · Developmental Neuroscience · doi:10.1159/000329424 · Cited by 25
Characterization of Potential Outcome Measures for Future Clinical Trials in Fragile X Syndrome
Berry‐Kravis, E., Sumis, A. M., Kim, O.-K., Lara, R., & Wuu, J. (2008) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-008-0564-8 · Cited by 25
Extinction of an instrumental response: a cognitive behavioral assay in Fmr1 knockout mice
Sidorov, M. S., Krueger‐Burg, D., Taylor, M. J., Gisin, E., Osterweil, E. K., & Bear, M. F. (2014) · Genes Brain & Behavior · doi:10.1111/gbb.12137 · Cited by 25
Human pathologies associated with defective RNA transport and localization in the nervous system
Dahm, R., & Macchi, P. (2007) · Biology of the Cell · doi:10.1042/bc20070045 · Cited by 24
Reducing glutamate signaling pays off in fragile X
Bassell, G. J., & Groß, C. (2008) · Nature Medicine · doi:10.1038/nm0308-249 · Cited by 24
Glutamate Receptors in Epilepsy
Bianchi, R., Wong, R. K. S., & Merlin, L. R. (2012) · Oxford University Press eBooks · doi:10.1093/med/9780199746545.003.0011 · Cited by 24
Results of a Nation-Wide Survey Evaluating Psychotropic Medication Use in Fragile X Syndrome
Valdovinos, M. G., Parsa, R. A., & Alexander, M. L. (2009) · Journal of Developmental and Physical Disabilities · doi:10.1007/s10882-008-9123-7 · Cited by 23
Increased 2-arachidonoyl-sn-glycerol levels normalize cortical responses to sound and improve behaviors in Fmr1 KO mice
Pirbhoy, P. S., Jonak, C. R., Syed, R., Argueta, D. A., Perez, P. A., Wiley, M. B., Hessamian, K., Lovelace, J. W., Razak, K. A., DiPatrizio, N. V., et al. (2021) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-021-09394-x · Cited by 24
Cellular and molecular mechanisms underlying autism spectrum disorders and associated comorbidities: A pathophysiological review
Dera, H. S. A. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112688 · Cited by 26
Fragile X syndrome: An aging perspective
Schneider, A., Ligsay, A., & Hagerman, R. J. (2013) · Developmental Disabilities Research Reviews · doi:10.1002/ddrr.1129 · Cited by 23
Behavior in a Drosophila Model of Fragile X
McBride, S. M. J., Bell, A. J., & Jongens, T. A. (2011) · Results and problems in cell differentiation · doi:10.1007/978-3-642-21649-7_6 · Cited by 24
Comparative psychopharmacology of autism and psychotic-affective disorders suggests new targets for treatment
Crespi, B. J. (2019) · Evolution Medicine and Public Health · doi:10.1093/emph/eoz022 · Cited by 24
3-Cyano-5-fluoro-N-arylbenzamides as negative allosteric modulators of mGlu5: Identification of easily prepared tool compounds with CNS exposure in rats
Felts, A. S., Lindsley, S. R., Lamb, J. P., Rodriguez, A. L., Menon, U. N., Jadhav, S. B., Jones, C. K., Conn, P. J., Lindsley, C. W., & Emmitte, K. A. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.06.064 · Cited by 22
Enhanced mGlu5-receptor dependent long-term depression at the Schaffer collateral-CA1 synapse of congenitally learned helpless rats
Pignatelli, M., Vollmayr, B., Richter, S. H., Middei, S., Matrisciano, F., Molinaro, G., Nasca, C., Battaglia, G., Ammassari‐Teule, M., Feligioni, M., et al. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.05.046 · Cited by 23
Platelets as a surrogate disease model of neurodevelopmental disorders: Insights from Fragile X Syndrome
Pellerin, D., Lortie, A., & Corbin, F. (2017) · Platelets · doi:10.1080/09537104.2017.1317733 · Cited by 25
MTEP, a Selective mGluR5 Antagonist, Had a Neuroprotective Effect but Did Not Prevent the Development of Spontaneous Recurrent Seizures and Behavioral Comorbidities in the Rat Lithium–Pilocarpine Model of Epilepsy
Dyomina, A. V., Kovalenko, A. A., Zakharova, M. V., Postnikova, T. Y., Griflyuk, A. V., Smolensky, I. V., Antonova, I., & Zaitsev, A. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23010497 · Cited by 21
Dose‐dependent, saturable occupancy of the metabotropic glutamate subtype 5 receptor by fenobam as measured with [11C]ABP688 PET imaging
Mathews, W. B., Kuwabara, H., Stansfield, K. H., Valentine, H., Alexander, M., Kumar, A., Hilton, J., Dannals, R. F., Wong, D. F., & Gasparini, F. (2014) · Synapse · doi:10.1002/syn.21775 · Cited by 21
An experimentally validated approach to automated biological evidence generation in drug discovery using knowledge graphs
Sudhahar, S., Özer, B., Chang, J., Chadwick, W., O’Donovan, D., Campbell, A., Tulip, E., Thompson, N. T., & Roberts, I. (2024) · Nature Communications · doi:10.1038/s41467-024-50024-6 · Cited by 21
The Implication of AMPA Receptor in Synaptic Plasticity Impairment and Intellectual Disability in Fragile X Syndrome
Cheng, G.-R., LI, X.-Y., XIANG, Y.-D., LIU, D., McClintock, S. M., & ZENG, Y. (2017) · Physiological Research · doi:10.33549/physiolres.933473 · Cited by 21
Group I metabotropic glutamate receptor mediated dynamic immune dysfunction in children with fragile X syndrome
Careaga, M., Noyon, T., Basuta, K., Van de Water, J., Tassone, F., Hagerman, R. J., & Ashwood, P. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-110 · Cited by 20
Genetic rodent models of brain disorders: Perspectives on experimental approaches and therapeutic strategies
McGraw, C. M., Ward, C. S., & Samaco, R. C. (2017) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.31570 · Cited by 24
Increasing our understanding of human cognition through the study of fragile X syndrome
Cook, D., Nuro, E., & Murai, K. K. (2013) · Developmental Neurobiology · doi:10.1002/dneu.22096 · Cited by 22
A Hypothesis Regarding the Molecular Mechanism Underlying Dietary Soy-Induced Effects on Seizure Propensity
Westmark, C. J. (2014) · Frontiers in Neurology · doi:10.3389/fneur.2014.00169 · Cited by 20
Frequency of FMR1 premutation carriers and rate of expansion to full mutation in a retrospective diagnostic FMR1 Korean sample
Jang, J. ‐., Lee, K., Cho, E. ‐., Lee, E. ‐., Kim, J. ‐., & Ki, C. (2013) · Clinical Genetics · doi:10.1111/cge.12195 · Cited by 19
Progress in Cytogenetics: Implications for Child Psychopathology
Hoffman, E. J., & State, M. W. (2010) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2010.03.016 · Cited by 19
Using Drosophila as a tool to identify pharmacological therapies for fragile X syndrome
McBride, S. M. J., Holloway, S. L., & Jongens, T. A. (2012) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2012.09.005 · Cited by 21
Advancing the discovery of medications for autism spectrum disorder using new technologies to reveal social brain circuitry in rodents
Kas, M. J., Modi, M. E., Saxe, M., & Smith, D. G. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3464-y · Cited by 19
Pathophysiology of Epilepsy in Autism Spectrum Disorders
Stafstrom, C. E., Hagerman, P. J., & Pessah, I. N. (2012) · Oxford University Press eBooks · doi:10.1093/med/9780199746545.003.0071 · Cited by 19
Rescue of Fmr1 phenotypes with mGluR5 inhibitors: MRZ-8456 versus AFQ-056
Westmark, P. R., Dekundy, A., Gravius, A., Danysz, W., & Westmark, C. J. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.08.008 · Cited by 22
Plasticity of glutamate synaptic mechanisms
Nadler, J. V. (2010) · Epilepsia · doi:10.1111/j.1528-1167.2010.02803.x · Cited by 19
X-linked mental retardation and epigenetics
Froyen, G., Bauters, M., Voet, T., & Marynen, P. (2006) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2006.tb00526.x · Cited by 19
Structural and Functional Abnormalities in the Olfactory System of Fragile X Syndrome Models
Bodaleo, F. J., Tapia-Monsalves, C., Rio, C. A. C.-D., González-Billault, C. E., & Nunez-Parra, A. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00135 · Cited by 17
The Drosophila DmGluRA is required for social interaction and memory
Schoenfeld, B. P., Choi, R. J., Choi, C. H., Terlizzi, A. M., Hinchey, P., Kollaros, M., Ferrick, N. J., Koenigsberg, E., Ferreiro, D., Leibelt, D. A., et al. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00064 · Cited by 17
Genetics and neuropsychiatric disorders: treatment during adulthood
Ehninger, D., & Silva, A. J. (2009) · Nature Medicine · doi:10.1038/nm0809-849 · Cited by 21
Partial mGlu5 Negative Allosteric Modulator M-5MPEP Demonstrates Antidepressant-Like Effects on Sleep Without Affecting Cognition or Quantitative EEG
Holter, K. M., Lekander, A., LaValley, C. M., Bedingham, E. G., Pierce, B. E., Sands, L. P., Lindsley, C. W., Jones, C. K., & Gould, R. W. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.700822 · Cited by 18
Effects of clonidine and methylphenidate on motor activity in Fmr1 knockout mice
Wrenn, C. C., Heitzer, A. M., Roth, A. K., Nawrocki, L., & Valdovinos, M. G. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.11.035 · Cited by 20
Effect of risperidone treatment on insulin-like growth factor-1 and interleukin-17 in drug naïve first-episode schizophrenia
Chen, D., Li, H., Zhao, Q., Song, J., Chen, L., & Yu, J. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.113717 · Cited by 18
Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5
Felts, A. S., Saleh, S. A., Le, U., Rodriguez, A. L., Weaver, C. D., Conn, P. J., Lindsley, C. W., & Emmitte, K. A. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.10.024 · Cited by 17
Changes in insulin‐like growth factor signaling alter phenotypes in Fragile X Mice
Wise, T. L. (2016) · Genes Brain & Behavior · doi:10.1111/gbb.12340 · Cited by 16
Deciphering discord: How Drosophila research has enhanced our understanding of the importance of FMRP in different spatial and temporal contexts
Weisz, E. D., Monyak, R. E., & Jongens, T. A. (2015) · Experimental Neurology · doi:10.1016/j.expneurol.2015.05.015 · Cited by 16
Pharmacology and Genetics of Autism: Implications for Diagnosis and Treatment
Brkanac, Z., Raskind, W. H., & King, B. H. (2008) · Personalized Medicine · doi:10.2217/17410541.5.6.599 · Cited by 17
The mGluR5 antagonist AFQ056 does not affect methylation and transcription of the mutant FMR1 gene in vitro
Tabolacci, E., Pirozzi, F., Gomez‐Mancilla, B., Gasparini, F., & Neri, G. (2012) · BMC Medical Genetics · doi:10.1186/1471-2350-13-13 · Cited by 15
A mouse model of fragile X syndrome exhibits heightened arousal and/or emotion following errors or reversal of contingencies
Moon, J., Ota, K. T., Driscoll, L. L., Levitsky, D. A., & Strupp, B. J. (2008) · Developmental Psychobiology · doi:10.1002/dev.20308 · Cited by 15
Interaction between Ephrins and mGlu5 Metabotropic Glutamate Receptors in the Induction of Long-Term Synaptic Depression in the Hippocampus
Piccinin, S., Cinque, C., Calò, L., Molinaro, G., Battaglia, G., Maggi, L., Nicoletti, F., Melchiorri, D., Eusebi, F., Massey, P. V., et al. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.4834-09.2010 · Cited by 15
Phenotypic variability to medication management: an update on fragile X syndrome
Elhawary, N. A., AlJahdali, I. A., Abumansour, I. S., Azher, Z. A., Falemban, A. H., Madani, W. M., Alosaimi, W., Alghamdi, G., & Sindi, I. A. (2023) · Human Genomics · doi:10.1186/s40246-023-00507-2 · Cited by 15
Convergence on CaMK4: A Key Modulator of Autism-Associated Signaling Pathways in Neurons
Kaiser, J., Risteska, A., Muller, A. G., Sun, H., Lei, B., Nay, K., Means, A. R., Cousin, M. A., Drewry, D. H., Oakhill, J. S., et al. (2024) · Biological Psychiatry · doi:10.1016/j.biopsych.2024.10.012 · Cited by 16
Role of metabotropic glutamate receptors in CNS disorders
O’Connor, R. M., & Cryan, J. F. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511760334.017 · Cited by 15
Developmental changes in expression of inhibitory neuronal proteins in the Fragile X Syndrome mouse basolateral amygdala
Kratovac, S., & Corbin, J. G. (2013) · Brain Research · doi:10.1016/j.brainres.2013.08.052 · Cited by 14
Targeted treatments in fragile X syndrome
Hare, E. B., Hagerman, R. J., & Lozano, R. (2014) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2014.903795 · Cited by 14
Glutamate Receptors in Epilepsy: Group I mGluR-Mediated Epileptogenesis
Bianchi, R., Wong, R. K. S., & Merlin, L. R. (2012) · Europe PMC (PubMed Central) · Cited by 14
ß-Arrestin2 Couples Metabotropic Glutamate Receptor 5 to Neuronal Protein Synthesis and Is a Potential Target to Treat Fragile X
Auerbach, B. D., Lefkowitz, R. J., Stoppel, L. J., Senter, R. K., Preza, A. R., & Bear, M. F. (2017) · DSpace@MIT (Massachusetts Institute of Technology) · Cited by 14
Caveolin-1-Mediated Cholesterol Accumulation Contributes to Exaggerated mGluR-Dependent Long-Term Depression and Impaired Cognition in Fmr1 Knockout Mice
Luo, L., Yang, L., Zhang, K., Zhou, S., Wang, Y., Yang, L.-K., Feng, B., Liu, S., Wu, Y., Zhao, M., et al. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03269-z · Cited by 14
Taking STEPs Forward to Understand Fragile X Syndrome
Goebel-Goody, S. M., & Lombroso, P. J. (2011) · Results and problems in cell differentiation · doi:10.1007/978-3-642-21649-7_12 · Cited by 14
Evaluation of lorcaserin as an anticonvulsant in juvenile Fmr1 knockout mice
Saraf, T. S., Felsing, D. E., Armstrong, J. L., Booth, R. G., & Canal, C. E. (2021) · Epilepsy Research · doi:10.1016/j.eplepsyres.2021.106677 · Cited by 14
Differentiation of Neuronal Cells in Fragile X Syndrome
Castrén, M. L. (2006) · Cell Cycle · doi:10.4161/cc.5.14.3096 · Cited by 13
Pharmacology, Signaling and Therapeutic Potential of Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators
Kos, J. A., Langiu, M., Hellyer, S. D., & Gregory, K. J. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00213 · Cited by 13
A blueprint for research on Shankopathies: A view from research on autism spectrum disorder
Carbonetto, S. (2013) · Developmental Neurobiology · doi:10.1002/dneu.22150 · Cited by 13
Fragile X syndrome
Pietropaolo, S., & Subashi, E. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781107360556.014 · Cited by 12
Clinically-probed mechanisms of action in fragile-X syndrome fail to normalize translational EEG phenotypes in Fmr1 knockout mice
Janz, P., Bainier, M., Marashli, S., Gross, S., & Redondo, R. L. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110182 · Cited by 11
Social Interactions in the Clinic and the Cage: Toward a More Valid Mouse Model of Autism
Lahvis, G. P., & Black, L. M. (2010) · Neuromethods · doi:10.1007/978-1-60761-883-6_7 · Cited by 11
Ketogenic Diet Affects Sleep Architecture in C57BL/6J Wild Type and Fragile X Mice
Westmark, P. R., Gholston, A. K., Swietlik, T. J., Maganti, R. K., & Westmark, C. J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914460 · Cited by 12
Decisional Capacity for Informed Consent in Males and Females with Fragile X Syndrome
Wheeler, A., Wylie, A. C., Raspa, M., Villagomez, A. N., Miller, K. M., Edwards, A., DeRamus, M., Appelbaum, P. S., & Bailey, D. B. (2019) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-019-03930-4 · Cited by 11
Spontaneous seizures in adult Fmr1 knockout mice: FVB.129P2-Pde6b+ Tyr Fmr1/J
Armstrong, J. L., Saraf, T. S., Bhatavdekar, O., & Canal, C. E. (2022) · Epilepsy Research · doi:10.1016/j.eplepsyres.2022.106891 · Cited by 11
Across Dimensions: Developing 2D and 3D Human iPSC-Based Models of Fragile X Syndrome
Lee, A., Xu, J., Wen, Z., & Jin, P. (2022) · Cells · doi:10.3390/cells11111725 · Cited by 11
The complex genetics in autism spectrum disorders
Hua, R., Wei, M., & Zhang, C. (2015) · Science China Life Sciences · doi:10.1007/s11427-015-4893-5 · Cited by 11
Behavioral, neurotransmitter and transcriptomic analyses in male and female Fmr1 KO mice
McCarthy, D. M., Vied, C., Trupiano, M. X., Canekeratne, A. J., Wang, Y., Schatschneider, C. W., & Bhide, P. G. (2024) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2024.1458502 · Cited by 10
Vorinostat Corrects Cognitive and Non-Cognitive Symptoms in a Mouse Model of Fragile X Syndrome
Ding, Q., Wu, X., Li, X., & Wang, H. (2021) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab081 · Cited by 10
ErbB inhibition rescues nigral dopamine neuron hyperactivity and repetitive behaviors in a mouse model of fragile X syndrome
D’Addario, S. L., Rosina, E., Cenere, M. M., Bagni, C., Mercuri, N. B., & Ledonne, A. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02831-y · Cited by 9
The mGluR Theory of Fragile X: From Mice to Men
Stoppel, L. J., Osterweil, E. K., & Bear, M. F. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804461-2.00009-3 · Cited by 9
A DNAzyme based knockdown model for Fragile-X syndrome in zebrafish reveals a critical window for therapeutic intervention
Medishetti, R., Rani, R., Kavati, S., Mahilkar, A., Akella, V., Saxena, U., Kulkarni, P., & Sevilimedu, A. (2019) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2019.106656 · Cited by 9
Fragile X Mental Retardation Protein: Many Partners and Multiple Targets for a Promiscuous Function
Khandjian, E. W., Bechara, E., Davidovic, L., & Bardoni, B. (2005) · Current Genomics · doi:10.2174/138920205775067701 · Cited by 10
Altered brain serotonin 5-HT1A receptor expression and function in juvenile Fmr1 knockout mice
Saraf, T. S., Chen, Y., Tyagi, R., & Canal, C. E. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109774 · Cited by 9
Fragile X syndrome as a rare disease in China – Therapeutic challenges and opportunities
Jin, X., & Chen, L. (2015) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2014.01037 · Cited by 9
Effects of subtype-selective group I mGluR antagonists on synchronous activity induced by 4-aminopyridine/CGP 55845 in adult guinea pig hippocampal slices
Salah, A., & Perkins, K. L. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.04.010 · Cited by 9
Familial mental retardation: a review and practical classification
Maris, A. F., Barbato, I. T., Trott, A., & Montano, M. A. E. (2013) · Ciência & Saúde Coletiva · doi:10.1590/s1413-81232013000600023 · Cited by 11
Testing Fmr1KO Phenotypes in Response to GSK3 Inhibitors: SB216763 versus AFC03127
Westmark, P. R., Garrone, B., Ombrato, R., Milanese, C., Giorgio, F. P. D., & Westmark, C. J. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.751307 · Cited by 9
Implementation of a markerless motion analysis method to quantify hyperkinesis in males with fragile X syndrome
O’Keefe, J. A., Orías, A. A. E., Khan, H., Hall, D. A., Berry‐Kravis, E., & Wimmer, M. A. (2013) · Gait & Posture · doi:10.1016/j.gaitpost.2013.10.017 · Cited by 9
Plasticity of Glutamate Synaptic Mechanisms
Nadler, J. V. (2012) · Oxford University Press eBooks · doi:10.1093/med/9780199746545.003.0012 · Cited by 9
Discovery of VU0431316: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety
Bates, B. S., Rodriguez, A. L., Felts, A. S., Morrison, R. D., Venable, D. F., Blobaum, A. L., Byers, F. W., Lawson, K. P., Daniels, J. S., Niswender, C. M., et al. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.06.003 · Cited by 9
MPEP Attenuates Intrahepatic Fat Accumulation in Obese Mice
Ferrigno, A., Cagna, M., Bosco, O., Trucchi, M., Berardo, C., Nicoletti, F., Vairetti, M., & Pasqua, L. G. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076076 · Cited by 8
Molecular Genetics of Intellectual Disability
Bessa, C., Lopes, F., & Maciel, P. (2012) · InTech eBooks · doi:10.5772/31269 · Cited by 10

Authors: Yan, Q. J., Rammal, M., Tranfaglia, M., & Bauchwitz, R. P.
Affiliations: Columbia University (US)
Fraxa Research Foundation (US)
Corresponding author: Bauchwitz, R.P.
ORCID: Bauchwitz, R.P.
Venue: Neuropharmacology
Publisher: Elsevier BV
Published: 2005-12
Volume: 49
Issue: 7
Pages: 1053-1066
ISSN: 0028-3908 (ISSN-L)
DOI: 10.1016/j.neuropharm.2005.06.004
OpenAlex: W2094993063
Cited by: 521
References: 60
Citations by year: 2026: 6 · 2025: 7 · 2024: 8 · 2023: 10 · 2022: 12 · 2021: 16 · 2020: 13 · 2019: 10 · 2018: 12 · 2017: 28 · 2016: 26 · 2015: 26 · 2014: 30 · 2013: 45 · 2012: 47
FWCI: 13.31
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
doi.org/10.15223/policy-017 (stm-asf)
doi.org/10.15223/policy-037 (stm-asf)
doi.org/10.15223/policy-012 (stm-asf)
doi.org/10.15223/policy-029 (stm-asf)
doi.org/10.15223/policy-004 (stm-asf)
Locations: Neuropharmacology (publishedVersion)
PubMed (publishedVersion)
CogPrints (University of Southampton) (submittedVersion)
Funders: FRAXA Research Foundation
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
Keywords: fragile X syndrome, FMR1 gene, mGluR5, MPEP, audiogenic seizures, testicular enlargement, FMRP, drug tolerance, seizure susceptibility, mouse model
MeSH terms: Aging, Alleles, Animals, Drug Synergism, Exploratory Behavior, Female, Fragile X Syndrome, Genotype, Male, Mice, Inbred C57BL, Phenotype, Pyridines, Receptors, Metabotropic Glutamate, Epilepsy, Reflex, Mice, Fragile X Messenger Ribonucleoprotein 1, Receptor, Metabotropic Glutamate 5

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks